BeOne Medicines (ADR) (ONC)
Develops and commercializes oncology medicines through an in-house global model.
$364.07
vs last close−1.61 (−0.44%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 32.73% | 34.97M ADS | |
|---|---|---|---|
| 296 holders · as of Jun 30, 2026 | |||
| Other | 67.27% | 71.89M ADS | |
| remainder | |||
106.86M ADS as of Sep 14, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
13F, as of Jun 30, 2026
296 holders · 34.97M shares · 47 new positions · 173 increased · 65 reduced · 45 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 8.80M | 8.24% | +2.5K | Aug 14, 2026 |
| Primecap Management Co/CA/ | 5.01M | 4.69% | +32.8K | Aug 14, 2026 |
| Capital International Investors | 4.21M | 3.94% | +51.5K | Aug 12, 2026 |
| FMR LLC | 2.48M | 2.32% | −1.22M | Aug 13, 2026 |
| Capital World Investors | 2.25M | 2.11% | +626.9K | Aug 12, 2026 |
| Citadel Advisors LLC | 1.43M | 1.33% | +393.2K | Sep 2, 2026 |
| Temasek Holdings (Private) Ltd | 845.7K | 0.79% | −16.9K | Aug 7, 2026 |
| Price T Rowe Associates Inc /MD/ | 758.8K | 0.71% | +219.0K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 7.80% | 13D | Sep 16, 2026 | |
| Capital International Investors | 5.80% | 13G | May 13, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 8, 2026 | Xiaodong Wangdirector, other: Chair, Scientific Advisory Brd | Sale · 8 lots | 38,287 | $349.10 | 0 |
| Sep 1, 2026 | Titus B. Ballofficer: Principal Accounting Officer | Sale | 132 | $355.86 | 0 |
| Aug 25, 2026 | Xiaobin Wuofficer: President and COO | Sale | 280 | $380.00 | 0 |
| Aug 11, 2026 | Chan Henry Leeofficer: SVP, General Counsel | Sale | 2,666 | $360.00 | 0 |
| Aug 12, 2026 | John Oylerdirector, officer: Chief Executive Officer | Sale · 5 lots | 54,892 | $358.15 | 0 |
| Aug 11, 2026 | John Oylerdirector, officer: Chief Executive Officer | Sale · 9 lots | 70,907 | $361.90 | 54,892 |
| Aug 10, 2026 | John Oylerdirector, officer: Chief Executive Officer | Sale · 10 lots | 115,011 | $357.87 | 125,799 |
| Aug 3, 2026 | Aaron Rosenbergofficer: Chief Financial Officer | Sale | 1,157 | $312.72 | 0 |
| Jul 30, 2026 | Chan Henry Leeofficer: SVP, General Counsel | Sale | 1,044 | $323.69 | 0 |
| Jul 22, 2026 | Chan Henry Leeofficer: SVP, General Counsel | Sale | 1,669 | $325.00 | 0 |
House and Senate disclosures
Not reported.